Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 12, 2003, Pages 1-100

  Kane, John M ^a   Leucht, Stefan ^a   Carpenter, Daniel ^a   Docherty, John P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; PERPHENAZINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; STABILIZING AGENT; THIORIDAZINE; TIOTIXENE; TOPIRAMATE; TRAZODONE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

AGGRESSION; AMENORRHEA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONVALESCENCE; DECISION MAKING; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CHOICE; DYSPHORIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HEALTH SURVEY; HUMAN; HYPERTENSION; OBESITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RELAPSE; REMISSION; RISK FACTOR; SIDE EFFECT; SMOKING; SOCIAL PSYCHOLOGY; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; TREATMENT FAILURE; TREATMENT OUTCOME; VIOLENCE;

EID: 0141594923     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Djulbegovic B, Hadley T. Evaluating the quality of clinical guidelines: linking decisions to medical evidence. Oncology 1998;12:310-314
2. Shekelle PG, Kahan JP, Bernstein SJ, et al. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 1998;338:1888-1895
3. Kahn DA, Carpenter D, Docherty JP, et al. The Expert Consensus Guideline Series: Treatment of Bipolar Disorder. J Clin Psychiatry 1996;57(suppl 12a):1-88
4. McEvoy JP, Weiden PJ, Smith TE, et al. The Expert Consensus Guideline Series: Treatment of Schizophrenia. J Clin Psychiatry 1996;57(suppl 12b):1-58
5. March JS, Frances A, Carpenter D, et al. The Expert Consensus Guideline Series: Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58(suppl 4):1-72
6. Alexopoulos GS, Silver JM, Kahn DA, et al. The Expert Consensus Guideline Series: Treatment of Agitation in Older Persons With Dementia. Postgrad Med Special Report 1998; April: 1-88
7. McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999;60 (suppl 11):1-80
8. Foa EB, Davidson JRT, Frances A. The Expert Consensus Guideline Series: Treatment of Posttraumatic Stress Disorder. J Clin Psychiatry 1999;60(suppl 16):1-76
9. Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med Special Report 2000; April: 1-104
10. Rush AJ, Frances A. Expert Consensus Guideline Series: Treatment of Psychiatric and Behavioral Problems in Mental Retardation. AJMR 2000;105(3):159-228
11. Altshuler LL, Cohen LS, Moline ML, et al, eds. The Expert Consensus Guideline Series: Treatment of Depression in Women 2001. Postgrad Med Special Report 2001; March: 1-116
12. Conners CK, March JS, Frances A, et al. Expert Consensus Guideline Series: Treatment of Attention-Deficit/Hyperactivity Disorder. J Atten Disord 2001;4(suppl 1):S1-S128
13. Allen MH, Currier GW, Hughes DH, et al. The Expert Consensus Guideline Series: Treatment of Behavioral Emergencies. Postgrad Med Special Report 2001; May: 1-88
14. Alexopoulos GS, Katz IR, Reynolds CF, et al. The Expert Consensus Guideline Series: Treatment of Depressive Disorders in Older Patients. Postgrad Med Special Report 2001; October: 1-86
15. Kahn DA, Docherty JP, Carpenter D, et al. Consensus methods in practice guideline development: a review and description of a new method. Psychopharmacol Bull 1997;33:631-639
16. Brook RH, Chassin MR, Fink A, et al. A method for the detailed assessment of the appropriateness of medical technologies. Int J Tech Assess Health Care 1986;2:53-63
17. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(4 Suppl):1-63
18. Lehman AF, Steinwachs DM, and the Co-Investigators of the PORT Project. At issue: translating research into practice: the schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10
19. Wilcox RR. Introduction to Robust Estimation and Hypothesis Testing. San Diego: Academic Press; 1997
20. Schulz SC. Somatic treatment of schizophrenia. In: Kaplan HJ, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, Fourth Edition. Baltimore: Williams & Wilkins; 1995:987-998
21. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
22. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002;14:163-173
23. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188:1217-1219
24. Van Der Weide J, Steijns LS, Van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003;13:169-172
25. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003;28:99-112
26. Jeste DV, Lacro JP, Gilbert PL, et al. Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 1993;19:817-830
27. Keck PE, Cohen BM, Baldessarini RJ, et al. Time course of antipsychotic effects of neuroleptic drugs. Am J Psychiatry. 1989;146:1289-1292
28. Agid O, Kapur S, Arenovich T, et al. Delayed onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Schizophr Res 2003;60(suppl 1):309 (abstract)
29. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-399
30. Lee CT, Conde BJ, Mazlan M, et al. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific. J Clin Psychiatry 2002;63:569-576
31. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000;51:634-638
32. Leucht S, McGrath J, White P, et al. Carbamazepine augmentation for schizophrenia: how good is the evidence? J Clin Psychiatry 2002;63:218-224
33. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine of risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28:182-192
34. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002;28:105-109
35. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
36. Steingard S, Allen M, Schooler NR. A study of the pharmacologic treatment of medication-compliant patients who relapse. J Clin Psychiatry 1994;55:470-472
37. Byerly M, Fisher R, Rush AJ, et al. A comparison of clinician vs. electronic monitoring of antipsychotic adherence in schizophrenia. Presented at the ACNP Annual Meeting, December 10, 2002, San Juan, Puerto Rico
38. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
39. Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001;52:1510-1514
40. Clozaril package insert. Novartis Pharmaceuticals. January, 2003
41. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002;28:43-61
42. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-258
43. Keefe RS, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-222
44. Kavanagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002;62:743-755
45. Kern RS, Green MF, Marshall BD Jr, et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull 1999;25:223-232
46. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002;51:972-978
47. Centers for Disease Control. Update: prevalence overweight among children, adolescents and adults-United States 1988-1994. MMWR Morb Mortal Wkly Rep 1997;46:198-202
48. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220
49. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73
50. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinemia in women: pathophysiology, severity and consequences. Br J Psychiatry 2003;82:199-204
51. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai Conference on the Health Monitoring of Patients with Schizophrenia. Am J Psychiatry (submitted)
52. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
53. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995;52:173-188
54. Gaebel W. Intermittent medication - an alternative? Acta Psychiatr Scand Suppl 1994;382:33-38
55. Kissling W, Kane JM, Barnes TR, et al. Guidelines for neuroleptic relapse prevention in schizophrenia: towards consensus view. In: Kissling W, ed. Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Heidelberg: Springer; 1991:155-163
56. Pekkala E, Merinder L. Psychoeducation for schizophrenia (Cochrane Review). The Cochrane Library. Update Software, Oxford, 2003
57. Pharoah FM, Mari JJ, Streiner D. Family intervention for schizophrenia (Cochrane Review). Update Software, Oxford, 2003
58. Pitschel-Walz G, Leucht S, Bauml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia: a meta-analysis. Schizophr Bull 2001;27:73-92
59. Kemp R, Kirov G, Everitt B, et al. Randomised controlled trial of compliance therapy: 18-month follow-up. Br J Psychiatry 1998;172:413-419
60. Marshall, M., Lockwood, A. Assertive community treatment for people with severe mental disorders (Cochrane Review). Update Software, Oxford, 2003
61. Marshall M, Gray A, Lockwood A, et al. Case management for people with severe mental disorders (Cochrane Review). The Cochrane Library. Update Software, Oxford, 2003
62. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-299
63. Davis JM, Metalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773
64. Mentschel C, Leucht S, Kane J. Depot drugs may reduce relapses in schizophrenic outpatients: a meta-analysis. Presented at the 156th Meeting of the American Psychiatric Association, San Francisco, May 17-22, 2003.
65. Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-307
66. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992;53:426-433
67. Goldman RS, Axelrod BN, Tandon R, et al. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. Psychopathology 1993;26:122-126
68. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993;16:295-312
69. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330
70. Harvey PD, Howanitz E, Parrella M, et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry 1998;155:1080-1086
71. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000;26:119-136
72. Huppert JD, Weiss KA, Lim R, et al. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res 2001;51:171-180
73. Perlick D, Mattis S, Stastny P, et al. Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia. J Neuropsychiatry Clin Neurosci 1992;4:428-434
74. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Information on the CATIE Schizophrenia Trial can be obtained from the NIMH website (www.nimh.nih.gov/studies/catieschiz.cfm) and from the CATIE website (www.catie.unc.edu)